<p>Rein Therapeutics Inc., a clinical-stage biotechnology company, has released a corporate presentation outlining its progress in developing therapies for orphan pulmonary and fibrosis indications. The company’s lead candidate, LTI-03, is being evaluated as a potential treatment for idiopathic pulmonary fibrosis (IPF), with Phase 2 clinical trials underway. According to the presentation, LTI-03 demonstrated a favorable safety profile in Phase 1 trials, with no identified safety issues at the highest tested dose. The therapy works through a dual mechanism aimed at promoting alveolar epithelial cell survival and inhibiting profibrotic signaling. Initial interim data from the Phase 2 trial is anticipated in the second half of 2026. Other pipeline programs include LTI-01 for loculated pleural effusions and additional candidates targeting multiple fibrotic and pulmonary conditions. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief on January 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

SBIO

RNTX

<p>Rein Therapeutics Inc. has announced advancements in its pipeline for therapies targeting orphan pulmonary and fibrosis conditions. The lead candidate, LTI-03, is currently in Phase 2 trials for idiopathic pulmonary fibrosis (IPF) and has shown a favorable safety profile in Phase 1. The therapy promotes cell survival and inhibits profibrotic signaling. Initial data from the Phase 2 trial is expected in late 2026. Other programs include LTI-01 for pleural effusions and additional candidates for various fibrotic and pulmonary diseases.</p>

Reuters

Health Care Select Sector SPDR

ALPS Medical Breakthrough

Rein Therapeutics

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Rein Therapeutics Unveils Pipeline Advancements in Pulmonary and Fibrosis Therapies